Little is known about the natural history of LGV, including that in immunosuppressed persons. Theoretically, LGV may be more severe among immunosuppressed persons, or latent infection may reactivate with immunosuppression. To our knowledge, no comparative treatment trials examining outcomes for HIV-infected and -uninfected patients have been published. On the basis of clinical experience, standard treatment with doxycycline or erythromycin is recommended for HIV-infected patients. Delay in the resolution of symptoms may occur in immunosuppressed persons, and prolonged therapy may be required; therefore, HIV-infected persons should be closely monitored for relapse or treatment failure.